CN102416064A - Medicine for treating ulcerated chilblain - Google Patents
Medicine for treating ulcerated chilblain Download PDFInfo
- Publication number
- CN102416064A CN102416064A CN201110398631XA CN201110398631A CN102416064A CN 102416064 A CN102416064 A CN 102416064A CN 201110398631X A CN201110398631X A CN 201110398631XA CN 201110398631 A CN201110398631 A CN 201110398631A CN 102416064 A CN102416064 A CN 102416064A
- Authority
- CN
- China
- Prior art keywords
- chilblain
- medicine
- oleum
- radix
- ulceration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 208000010445 Chilblains Diseases 0.000 title claims abstract description 26
- 229940079593 drug Drugs 0.000 title description 7
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims abstract description 16
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims abstract description 9
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 9
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000004327 boric acid Substances 0.000 claims abstract description 8
- 208000025865 Ulcer Diseases 0.000 claims description 28
- 230000036269 ulceration Effects 0.000 claims description 15
- 229940025250 camphora Drugs 0.000 claims description 8
- 239000010238 camphora Substances 0.000 claims description 8
- 210000000582 semen Anatomy 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 11
- 230000008961 swelling Effects 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 7
- 230000006872 improvement Effects 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 abstract 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 abstract 1
- 241000723346 Cinnamomum camphora Species 0.000 abstract 1
- 241001071917 Lithospermum Species 0.000 abstract 1
- 244000028419 Styrax benzoin Species 0.000 abstract 1
- 235000000126 Styrax benzoin Nutrition 0.000 abstract 1
- 235000008411 Sumatra benzointree Nutrition 0.000 abstract 1
- 229960002130 benzoin Drugs 0.000 abstract 1
- 229960000846 camphor Drugs 0.000 abstract 1
- 229930008380 camphor Natural products 0.000 abstract 1
- 235000019382 gum benzoic Nutrition 0.000 abstract 1
- 229940041616 menthol Drugs 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 description 13
- 230000036407 pain Effects 0.000 description 10
- 239000002674 ointment Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 208000003251 Pruritus Diseases 0.000 description 6
- 210000005069 ears Anatomy 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 206010040882 skin lesion Diseases 0.000 description 5
- 231100000444 skin lesion Toxicity 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 208000009084 Cold Injury Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001139 anti-pruritic effect Effects 0.000 description 3
- 239000003908 antipruritic agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000002595 cold damage Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000003811 finger Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010043189 Telangiectasia Diseases 0.000 description 2
- 241000294142 Vascellum Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000005224 forefinger Anatomy 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000811 metacarpophalangeal joint Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000009056 telangiectasis Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 206010048961 Localised oedema Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- WNFXUXZJJKTDOZ-HNNXBMFYSA-N [(1s)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] acetate Chemical compound C1=CC(O)=C2C(=O)C([C@@H](OC(C)=O)CC=C(C)C)=CC(=O)C2=C1O WNFXUXZJJKTDOZ-HNNXBMFYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 238000009418 renovation Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- WNFXUXZJJKTDOZ-UHFFFAOYSA-N shikonin acetate Natural products C1=CC(O)=C2C(=O)C(C(OC(C)=O)CC=C(C)C)=CC(=O)C2=C1O WNFXUXZJJKTDOZ-UHFFFAOYSA-N 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009724 venous congestion Effects 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention is a medicament for the treatment of ulcerated chilblain, it is Chinese and western medicine and combines the prescription pharmaceutical field, the characteristic is made according to the weight proportion by camphor 0.5-1.5, menthol 0.5-1, resorcinol 8-15, boric acid 2-6, lanoline 8-15, oil of Lithospermum erythrorhizon 80-120 and benzoin of fat of rag 80-220, have apparent improvement and relieve local blood stasis swelling, painful sign and symptom function to ulcerated chilblain, the curative effect is unique; the cure rate reaches more than 70 percent, and the total effective rate reaches more than 90 percent; the recurrence rate is low.
Description
Technical field
The invention belongs to Chinese medicine and western medicine and combine the prescription medicine field, particularly being directed against, the Chinese medicine and western medicine of ulceration treatment of perniosis combines external ointment preparation.
Background technology
Chilblain belongs to physical property disease category, is a kind of skin limitation, congestion property, diseases associated with inflammation that betides the tip position of cold season.Be since the skin long term exposure in cold, malaria; The circulation of patient's peripheral blood is relatively poor in addition is main pathogenic factors, lacks motion, acrohyperhidrosis, malnutrition, anemia, footgear tension, outwork and Chronic consumptions and all can be the primary disease inducement.Endure cold the subcutaneous tremulous pulse in position owing to cold stimulation is shunk; Cause that the blood flow stasis of blood stagnates, histanoxia causes cells injury, as the time remaining time of enduring cold is long more, tremulous pulse continues spasm; Cause angioparalysis and go out venous congestion; Telangiectasis, permeability increases, and blood plasma infiltrates interstice and falls ill.The clinical manifestation of primary disease: primary disease is prone to sent out early winter, early spring, and each age group all can be fallen ill, and sees with child, young women or peripheral blood poor circulation person more.Good sending out in tip positions such as acra, auricle, noses.Skin lesion is a localized edema property purplish-red macula, by color move back, go to press its color of back to recover, when serious vesicle can be arranged, form ulcer behind the ulceration.There is the swelling sense part, itches pain then after festering after the warm heat.
Treatment: for the treatment of this disease, the following method of general clinically employing:
1, external medication: the chilblain clinical treatment of ulceration generally adopts symptomatic therapy; Local 3% borate temperature is applied; External is to skin mucosa nonirritant medicine, infection, and promotes the new granulation tissue regeneration of skin and epidermal tissue's renovation agent, like lidocaine gel, moist expose burn ointment etc.But clinical effectiveness is not very good.
2, innerlich anwenden thing treatment: mainly be medicament for expanding vascellum, and oral antibiotic anti-infective therapy, like oral nicotinic acid tablet, cephalosporins etc.Because of innings property inflammatory physical property disease of exceeding in view of chilblain, and medicament for expanding vascellum and antibiotic belong to systemic administration, and certain drug side effect is arranged, and particularly the teenager damage is bigger to human body.
Summary of the invention
The object of the present invention is to provide a kind of treatment medicine of ulceration chilblain, can effectively treat and prevent and alleviate the not generation of ulceration chilblain, cure rate be high.
The present invention is achieved in that
Treat the medicine of ulceration chilblain, it is characterized in that processing raw materials of effective components and form and to be: Camphora 0.5-1.5, Mentholum 0.5-1, resorcinol 8-15, boric acid 2-6, lanoline 8-15, Oleum Radix Arnebiae (Oleum Radix Lithospermi) 80-120 and adeps benzoinatus 80-220 by its weight proportion.
Said Oleum Radix Arnebiae (Oleum Radix Lithospermi) is made by Radix Arnebiae (Radix Lithospermi), Cortex Phellodendri, Cortex Cinnamomi and Radix Et Rhizoma Rhei and Oleum Arachidis hypogaeae semen heating, and its weight proportion is: Radix Arnebiae (Radix Lithospermi) 100, Cortex Phellodendri 50, Cortex Cinnamomi 50, Radix Et Rhizoma Rhei 50 and Oleum Arachidis hypogaeae semen 1000.
Through clinical property pharmacological toxicology research, the present invention has following clinical effectiveness:
1, ulceration chilblain is had clear improvement and alleviate the S&S effect of local congestion swelling, pain, special effect;
2, external preparation has no side effect to health;
3, treat that the ulceration chilblain is evident in efficacy, cure rate reaches more than 70%, and total effective rate reaches more than 90%;
4, relapse rate is low.
Pharmacology analysis:
Camphora: Camphora is the local excitation medicine, is used for the part and can makes skin small artery and telangiectasis, causes that cutaneous circulation increases, and also has pain relieving, itching-relieving action.
Mentholum: after Mentholum is used for skin; Can optionally act on the skin Cold receptor; The reflection of the generation sense of cold causes skin, mucosa vasoconstriction, and the blood vessel for deep tissue also has reflexive to change simultaneously; Therefore, produce refrigerant sense, antipruritic, pain relieving, alleviate edema and counterirritantion.
Resorcinol: have antibacterial, antifungal and itching-relieving action, its bactericidal action is 1/3 of a phenol, and its zest and corrosivity are also little, and low concentration has keratinization to facilitate effect, and high concentration has cutin to strip off effect.
Boric acid: being demulcent convergence antiseptic, is a weak acid, can get in the microbial cell, discharges hydrion and weak bacteriostasis takes place, and zest is little.
Lanoline: protection, lubrication are arranged; And be the substrate commonly used of preparation Emulsion and ointment; Can promote penetrating and absorbing of principal agent in Emulsion or the ointment, simultaneously because of the performance of stronger absorption secretions is arranged, be the ointment shortcoming in this respect of substrate thereby can overcome with vaseline.
Oleum Radix Arnebiae (Oleum Radix Lithospermi): the aubergine oily liquids has special smelly.Have antiinflammatory, removing the necrotic tissue and promoting granulation effect.Be used to treat dermatosiss such as burn and scald, knife injury, eczema, diaper dermatitis, otitis media, vulvitis, cervicitis and blister.Oleum Radix Arnebiae (Oleum Radix Lithospermi) is made by Radix Arnebiae (Radix Lithospermi), Cortex Phellodendri, Cortex Cinnamomi and Radix Et Rhizoma Rhei and Oleum Arachidis hypogaeae semen heating; Contain red etc. in the Radix Arnebiae (Radix Lithospermi) just like acetylshikonin, Radix Arnebiae (Radix Lithospermi); All dissolve in the vegetable oil; That these compositions have is antibiotic, antiinflammatory, detumescence, granulation promoting, antiviral and Detoxication, surplus Cortex Phellodendri, Cortex Cinnamomi, Radix Et Rhizoma Rhei all have detoxifcation, antibacterial, anticorrosion, improve pharmacological actions such as local microcirculation, analgesia and antiulcer.
Adeps benzoinatus: the effect of protection is arranged, lubricating, growing gentle skin.Be used for that drying is chapped and the desquamation dermatoses, still can make ointment base, its Transdermal absorption ability and be strong all than vaseline to the release of medicine.
The prescription analysis-by-synthesis:
This prescription is the prescription that share for Chinese and western drugs; Its division of Western drugs branch basis is carried out reasonable compatibility with the requirement of using for reference the Pharmacopoeia of the People's Republic of China and " Chinese Hospitals preparation standard "; The prescription science, rigorous, select medicine to investigate (clinical application all is the medical raw material of the accurate font size of traditional Chinese medicines), in conjunction with our institute for many years several Chinese medicine composition of clinical experience gained refinforce each other together, be to be characteristic external preparation blending the east and the west; It also is the development of must walking to look for novelty of clinical external preparation; To sum up state, this prescription external preparation has the local congestion swelling of improvement, antiinflammatory, antipruritic, pain relieving, repairs and pharmacological actions such as promotion ulcer healing and shortening ulcer time of origin; Accomplished the reasonable scientific matching of Chinese and western drugs; Actually be the external preparation of the special for treating ulceration chilblain blending the east and the west that must promote of a class value, clinical treatment and preventive effect receive the consistent favorable comment of this county chilblain patient really, for numerous chilblain patients has removed inconvenience ailing and that bring thus.
The specific embodiment
Below in conjunction with this embodiment the present invention is elaborated.
Embodiment 1
The present invention adopts following method to make:
1, get Camphora 1g, Mentholum 0.6g, resorcinol 10g and mix and grind in the rearmounted mortar to complete liquefaction, as subsequent use medicinal liquid I, for use;
2, get adeps benzoinatus 80g and put into container and be built in heating and melting in the water-bath, make its temperature not surpass 60 ℃, add lanoline 10g again and in the adeps benzoinatus that melts, it is mixed, temperature can not surpass 60 ℃, and is as subsequent use medicinal liquid II, for use;
3, subsequent use medicinal liquid I and subsequent use medicinal liquid II are mixed, it is mixed once more fully, temperature can not surpass 60 ℃, obtains subsequent use medicinal liquid III;
4, one by one boric acid 4g, Oleum Radix Arnebiae (Oleum Radix Lithospermi) 100g, distilled water 10ml are added among the subsequent use medicinal liquid III, be stirred to condensation along same direction always and promptly get.
Distilled water: promptly refer in particular to the special-purpose distilled water of pharmaceutical sector, agent is used as the dilution solvent.
The manufacture method of Oleum Radix Arnebiae (Oleum Radix Lithospermi): Oleum Arachidis hypogaeae semen 1000g is heated to 180 ℃, the Radix Arnebiae (Radix Lithospermi) 100g that shreds, Cortex Phellodendri 50g, Cortex Cinnamomi 50g, Radix Et Rhizoma Rhei 50g are added successively, stirred 5 minutes, while hot with four layers of gauze filtering medicinal residues, both.
The The Characters of medicine of the present invention, is applied with warm water temperature earlier and is cleaned the affected part during use for for dark violet red ointment, wipes away ointment to be applied to the affected part and gently to rub to have to generate heat to the part and feel every day 2～3 times after doing.Have antiinflammatory, antipruritic, blood circulation promoting, promotion ulcer healing and shorten effects such as ulcer time of origin, protection, be mainly used in treatment and prevent the chilblain of ulceration.
Embodiment 2
Get Camphora 0.5, Mentholum 0.5, resorcinol 8, boric acid 2, lanoline 8, Oleum Radix Arnebiae (Oleum Radix Lithospermi) 80 and adeps benzoinatus 100, manufacture method is with embodiment 1.
Embodiment 3
Get Camphora 1.5, Mentholum 1, resorcinol 15, boric acid 6, lanoline 15, Oleum Radix Arnebiae (Oleum Radix Lithospermi) 120 and adeps benzoinatus 220.
Clinical trial
Be checking medicine of the present invention, the applicant carried out following clinical trial in 2006～2010 years in Donga, Shandong Province county institute of internal medicine:
1, clinical data
All case amounts to 100 examples all from Donga, Shandong Province county institute of internal medicine, and above-mentioned patient is divided into two groups at random, and one group is the treatment group, amounts to 50 examples; Another group is matched group, amounts to 50 examples.
2, Therapeutic Method
The treatment group adopts medicine of the present invention, embrocates external on request 2 times every day, and per 7 days is a course of treatment.
Matched group is coated with commercially available kibe ointment (the accurate word H42020886 of field pharmaceutcal corporation, Ltd of Hubei section traditional Chinese medicines) outward, and every day 2 times is embrocated per 7 days one courses of treatment by its requirement.
3, therapeutic evaluation standard
Chilblain as clinical can name 2000 surplus one of kind of cutaneous diseases, not have the concrete clinical cure standard of ten minutes standard at present yet, mainly be that therapeutic evaluation is carried out in the clinical symptoms according to primary disease, the improvement and the disappearance of sign.
Cure: the inflammatory congestion swelling of skin lesion, and the dark violet red color complete obiteration of skin lesion, the shallow pigmentation spots of short period is only left in the affected part, patient's pain, very clinical symptoms complete obiteration such as itch;
Effectively: patient's symptom and affected part sign have clear improvement, like the alleviation of congestion swelling and the alleviation of pain gargalesthesia;
Invalid: patient's clinical symptoms and sign all do not have to improve and alleviate.
4, efficacy result
The curative effect data see the following form:
Recurrence situation: through behind the clinical cure,, in cold season or environment, still can send out again, paid a return visit recurrence situation such as following table through 2 years owing to reasons such as patient self body opposing function and warming improper measures:
5, conclusion
For the treatment and the prevention of ulceration chilblain very ideal curative effect is arranged through the visible the present invention of above-mentioned clinical trial, and cure rate, total effective rate be apparently higher than other drug, relapse rate is significantly less than other drug.
6, concrete case
Case 1, field, woman 8 years old; Donga County, Shandong frontier passes and mountains village people is in 2009 02 month No. 10, because of its right hand metacarpophalangeal joints dorsal part and forefinger, middle finger the cold injury situation occurs and go to a doctor in my institute; Relevant history of past illness: the family numbers of patients readme once had similar cold injury history before this winter, physical examination: the red and swollen color purpura of inflammatory appears in right hand metacarpophalangeal joints dorsal part and forefinger, middle finger, and the about 4*4m2 of skin lesion area particularly is positioned at the skin lesion centre has as the similar coin aphtha greatly; Ulcer surface is rotten to the corn, upward with the rheuminess thing, and patient's readme inconvenience of counting on one's fingers; Local distending pain is obvious, and temperature is crossed when warming up and felt again to scratch where it itches.Reaching on inspection according to the past patient all has chilblain generation medical history situation winter, can clearly make a definite diagnosis this patient and meet " the concurrent ulcer diagnosis of chilblain ".With giving the externally-applied soft ointment that this institute is invented above-mentioned prescription; Concrete method for using; Applied the affected part 10～30 minutes with the warm water temperature earlier, then medicine of the present invention is taken advantage of the local warm affected part that is applied to and also do soft massage 3～5 minutes, to promote the absorption of medicine; Twice external every day, treating 7 continuously is a course of treatment.
Patient's further consultation once more after 7 days, the purple sign of the local swelling stasis of blood is alleviated fully, and ulcer surface heals basically, and the also complete obiteration of patient's readme pain gargalesthesia symptom reaches clinical cure basically.
Case 2, stone, man 42 years old, ancient Guan Tunshi people from village in Donga County, Shandong, the builder is in 2009 02 month No. 29, because of going to a doctor to me along cold injury in its ears outside.Relevant history of past illness: the patient did not have the chilblain medical history from before this.Physical examination: red and swollen congestion phenomenon all appears in the wide outer of visible ears; There is shallow table ulcer at the vertical red and swollen place of auris dextra, the rotten to the corn inflammatory exudation of ulcer surface, and left ear-lobe only has purple the swelling of swelling and ulcer do not occur; The ulcer healing face that has two to three places to form a scab in nearly upper end, the wide outer of ears like the beans size; Readme pain is sometimes very itched sometimes, and special evening very itches owing to warm heat effect shows as night in sleeping back, is diagnosed as " the ears chilblain is also accompanied ulcer " after diagnosing according to obvious clinical symptoms and sign.Give prescription external used medicine of the present invention immediately, by every day twice local topical, logotype 7th was a course of treatment, after follow up a case by regular visits to, fully recover.
Claims (3)
1. treat the medicine of ulceration chilblain, it is characterized in that processing raw materials of effective components and form and to be: Camphora 0.5-1.5, Mentholum 0.5-1, resorcinol 8-15, boric acid 2-6, lanoline 8-15, Oleum Radix Arnebiae (Oleum Radix Lithospermi) 80-120 and adeps benzoinatus 80-220 by its weight proportion.
2. treatment according to claim 1 is the medicine of ulceration chilblain, it is characterized in that wherein processing raw materials of effective components composition and weight proportion to be: Camphora 1, Mentholum 0.6, resorcinol 10, boric acid 4, lanoline 10, Oleum Radix Arnebiae (Oleum Radix Lithospermi) 100 and adeps benzoinatus 80.
3. treatment according to claim 1 and 2 is the medicine of ulceration chilblain; It is characterized in that said Oleum Radix Arnebiae (Oleum Radix Lithospermi) is made by Radix Arnebiae (Radix Lithospermi), Cortex Phellodendri, Cortex Cinnamomi and Radix Et Rhizoma Rhei and Oleum Arachidis hypogaeae semen heating, its weight proportion is: Radix Arnebiae (Radix Lithospermi) 100, Cortex Phellodendri 50, Cortex Cinnamomi 50, Radix Et Rhizoma Rhei 50 and Oleum Arachidis hypogaeae semen 1000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110398631XA CN102416064A (en) | 2011-11-26 | 2011-11-26 | Medicine for treating ulcerated chilblain |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110398631XA CN102416064A (en) | 2011-11-26 | 2011-11-26 | Medicine for treating ulcerated chilblain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102416064A true CN102416064A (en) | 2012-04-18 |
Family
ID=45940865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110398631XA Pending CN102416064A (en) | 2011-11-26 | 2011-11-26 | Medicine for treating ulcerated chilblain |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102416064A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772485A (en) * | 2012-07-11 | 2012-11-14 | 马占国 | External multi-functional ointment for clearing away heat and toxic materials |
| CN103285035A (en) * | 2013-07-01 | 2013-09-11 | 戴丽芬 | Medicine for treating dry skin chilblain and manufacturing method thereof |
| CN103720133A (en) * | 2014-01-17 | 2014-04-16 | 安徽省泗州鞋业有限公司 | Medical insole with effect of preventing and treating chilblain and preparation method thereof |
-
2011
- 2011-11-26 CN CN201110398631XA patent/CN102416064A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772485A (en) * | 2012-07-11 | 2012-11-14 | 马占国 | External multi-functional ointment for clearing away heat and toxic materials |
| CN103285035A (en) * | 2013-07-01 | 2013-09-11 | 戴丽芬 | Medicine for treating dry skin chilblain and manufacturing method thereof |
| CN103720133A (en) * | 2014-01-17 | 2014-04-16 | 安徽省泗州鞋业有限公司 | Medical insole with effect of preventing and treating chilblain and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017206758A1 (en) | Topical pharmaceutical composition for treating multiple forms of skin wounds and manufacturing method thereof | |
| CN103191257A (en) | Bone healing tincture | |
| CN101703651A (en) | Medicament for treating diabetic gangrene | |
| CN102416064A (en) | Medicine for treating ulcerated chilblain | |
| CN102861217A (en) | External emplastrum for treating malignant boil, sores and carbuncles | |
| CN101433617B (en) | Disinfecting paste for dissolving wart and eliminating wart | |
| CN101310750B (en) | A kind of external medicine for treating soft tissue injury and preparation method thereof | |
| CN100438896C (en) | External use muscle relaxing preparation for treating traumatic injury and rheumatism stagnation pain and its preparing method | |
| CN102370777A (en) | Medicament for treating non-ulcerated chilblains | |
| CN101856479B (en) | Chinese medicament for treating psoriasis vulgaris and preparation method thereof | |
| CN101406583B (en) | Externally applied Chinese medicine ointment for treating pyogenic skin infection caused by skin traumatism | |
| CN104491629A (en) | External traditional Chinese medicinal composition for treating perianal eczema, and preparation method thereof | |
| CN103977113A (en) | Traditional Chinese medicament for treating diabetic foot | |
| CN101983650A (en) | Medicament for treating dermatitis aestivale | |
| CN100348239C (en) | Traditional Chinese medicine preparation for treating soft tissue pain and preparation method | |
| CN105125708A (en) | Pharmaceutical composition for treating rhinitis and preparation method thereof | |
| CN104474405A (en) | Traditional Chinese medicine composition for treating chloasma | |
| CN105168503B (en) | It is a kind of to be used to prevent external medicine composition of radiodermatitis and preparation method thereof | |
| CN104288368B (en) | A kind of externally applied spray for treating seasonly cutaneous itching disease | |
| CN103070994B (en) | Plaster for treating cervical and lumbar spondylosis | |
| CN103893669B (en) | Traditional Chinese medicine composition for treating tinea pedis and preparation method and application thereof | |
| CN102225125B (en) | Externally applied traditional Chinese medicine composite for treating joint pain caused by rheumatoid arthritis and preparation method thereof | |
| CN101607069B (en) | Chinese traditional medicine for treating phlebitis, old lower extremity venous ulcer and venous purpura disease | |
| CN103599230A (en) | Medicine for treating ulcerated chilblain | |
| CN106729427B (en) | External Chinese medicinal composition for treating rheumatism and cold arthralgia, using method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120418 |